Kodiak Sciences (NASDAQ:KOD), Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for retinal diseases. Headquartered in Palo Alto, California, Kodiak leverages proprietary antibody biopolymer conjugate (ABC) technology to create targeted treatments that aim to improve durability, durability and efficacy in the eye. The company was founded in 2009 and has steadily advanced a pipeline of product candidates designed to address unmet needs in chronic ophthalmic conditions.
The company’s lead candidate, KSI-301, is an anti-VEGF antibody biopolymer conjugate that is being evaluated in pivotal Phase 3 studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). By combining a high-molecular-weight polymer with an anti-VEGF antibody, KSI-301 is engineered to extend treatment intervals and potentially reduce the frequency of intravitreal injections for patients. Kodiak has also initiated early-stage programs exploring novel targets in retinal vascular disease and inherited retinal disorders.
Kodiak Sciences operates research and development facilities in both the United States and Europe, enabling global collaboration and clinical trial execution across multiple geographies. The company has established strategic partnerships with academic institutions and contract research organizations to support its translational efforts. Kodiak’s international reach is further strengthened by regulatory interactions in key markets, positioning the company to seek approvals and commercial launches in North America, Europe and select Asia-Pacific territories.
Leadership at Kodiak Sciences includes President and Chief Executive Officer Victor Perlroth, who brings extensive experience in ophthalmology drug development, and Chief Medical Officer Manjula Mahajan, M.D., a recognized expert in retinal disease clinical research. The management team and board combine scientific, clinical and commercial expertise to drive the advancement of Kodiak’s pipeline. As Kodiak continues its late-stage programs, the company remains committed to delivering transformative therapies for patients suffering from vision-threatening conditions.
